Dihexa: research reference

Describe the model before the result. A cellular signal, behavioral observation and clinical outcome are not interchangeable evidence labels.

The proposed interaction with the HGF/c-Met system comes, in part, from an article retracted in 2025. In preclinical models, another study examined the involvement of PI3K/AKT; that finding does not, by itself, confirm the proposed molecular interaction.

The purity value is a product-label specification, not an assay result. A batch result can only be asserted from that batch’s certificate.

These names help identify the catalog entry. A descriptive label is not evidence of efficacy, and structural identity still requires appropriate documentation.

Neuroactive compound

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Personal protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

The 2024 paper identifies PNB-0408 as Dihexa and places it among angiotensin IV analogs. This documented name equivalence concerns the studied compound; it does not make native angiotensin IV or other derivatives interchangeable.

The commercial reference declares Dihexa as its ingredient. Animal-study preparations, experimental vehicles and combinations must be identified separately. A related-analog publication does not automatically document this ingredient or vial contents. Sources: PMID 38489193; PMID 34703584.

The 2014 paper linking these derivatives’ findings to HGF/c-Met was retracted through a notice published in 2025. Its mechanistic conclusions cannot serve as current supporting evidence. It may be discussed as historical background only with its retracted status explicit.

The 2013 Dihexa characterization paper has a 2021 editorial expression of concern linked in PubMed. An expression of concern and a retraction are different statuses: the former applies to the 2013 record, the latter to the 2014 paper. This distinction matters for claims about stability, nervous-system access and experimental outcomes from those works. Sources: PMID 40312093; PMID 34551989; PMID 23055539.

A 2021 publication examined Dihexa in APP/PS1 mice using a water maze, tissue analysis and molecular markers. The authors observed favorable spatial-learning changes and differences in neuronal and inflammatory markers within that model.

Wortmannin experiments supported PI3K/AKT involvement in some findings. They do not establish direct Dihexa–HGF binding. Measuring an intracellular pathway and identifying a molecular interaction are separate questions even when linked by a hypothesis. Sources: PMID 34827486.

The 2024 study evaluated PNB-0408 in rats exposed to 3-nitropropionic acid, abbreviated 3-NP. Weight, motor function, learning and histopathology were assessed. The authors observed no protection against model deficits under the examined conditions.

This negative finding must remain visible alongside APP/PS1 research. Different experimental causes and outcomes mean they are not direct replications, but they also do not support a general favorable-response claim across neurological models. Sources: PMID 38489193; PMID 34827486.

Another 2021 study examined rat sciatic-nerve injury and surgical repair, comparing mesenchymal cells, G-CSF, Dihexa and combinations, including local hydrogel preparations. The highlighted motor differences concerned particular combinations with mesenchymal cells.

That design cannot be summarized as an isolated-ingredient result. Hydrogel, cells and other materials are part of the experimental conditions. They are not formulations of this commercial product, and the paper does not certify its composition or batch properties. Sources: PMID 34703584.